logo
    • English
      • 简体中文
      • 繁體中文
  • Home
  • Articles
    • Insights
    • Client Press Releases
    • Client Coverage
  • Interviews
    • CEO Interview
    • PDAC Interview
  • Clients
    • Featured Companies
    • In-depth Analysis
  • Markets
    • Stock Tracker
    • Markets at a glance
    • Investing 101
      • Investing in Mining 101
        • Gold and Precious Metals
        • Electric and Battery Metals
        • Base Metals
        • Other Mining Subsectors
  • METALS 100
  • GCFF Event
    • Next Event
    • Past Events
  • Home
  • Trends & Strategies
  • Life Science & Technology Weekly 146 – Frontier Biotech’s HIV Drug Approved, First China-Developed HIV Treatment

Life Science & Technology Weekly 146 – Frontier Biotech’s HIV Drug Approved, First China-Developed HIV Treatment

NAI Life Science & Technology - www.nai500.com
Published on: Jun 7, 2018
Author: Editor
  • Share article:

 

Check www.nai500.com for more investment opportunities

Click here to find more details

This is NAI’s new Life Science and Technology Weekly. We will be covering the latest news in life science, pharmaceutical, biotech and technology sectors every week. To continue to receive NAI’s Life Science and Technology Weekly, please click Here to subscribe.

Biotechnology Blockchain Life Science Pharmaceutical Technology

Related Posts

Apple Tops Nvidia in Market Cap, but the Valuation Gap Tells a Different Story

Apple Tops Nvidia in Market Cap, but the Valuation Gap Tells a Different Story

Helium Shortage Threatens AI Chip Production, Upends Global Supply Chains

Market Misjudges AI Threat, Making Alphabet the Most Undervalued Among the Magnificent Seven

联合健康与礼来,谁将引领市场?

Bristol-Myers Squibb Beats Estimates in Q2, Stock Outperforms Market on Thursday

比特币下跌之际,Cipher Mining (CIFR) 为何能强势上涨?

The Traditional Mining Machine Hosting Business Has Slightly Declined, While Applied Digital Reshapes Its Growth Trajectory With AI Computing Infrastructure

Canada’s Move on China-Made EVs Opens Door for Tesla

Profit Slump Coupled with Surging Capital Expenditure, Can Tesla Hold Onto Its Trillion-Dollar Market Cap?

“美股七巨头",就是谁才是真正的性价比之王?

Alphabet’s 17x P/E Makes It the Magnificent Seven’s Biggest Bargain

Related News

Apple Tops Nvidia in Market Cap, but the Valuation Gap Tells a Different Story

5 hours ago.

Market Misjudges AI Threat, Making Alphabet the Most Undervalued Among the Magnificent Seven

9 hours ago.

Bristol-Myers Squibb Beats Estimates in Q2, Stock Outperforms Market on Thursday

10 hours ago.

The Traditional Mining Machine Hosting Business Has Slightly Declined, While Applied Digital Reshapes Its Growth Trajectory With AI Computing Infrastructure

11 hours ago.

Top Stories

Apple, Amazon Diverge Post-Earnings: 6% Slump vs 8% Rally
Technology

Apple, Amazon Diverge Post-Earnings: 6% Slump vs 8% Rally

Same AI Bet, Divergent Fates: Why Meta Tumbled and Microsoft Surged
Technology

Same AI Bet, Divergent Fates: Why Meta Tumbled and Microsoft Surged

We connect Investors to Opportunities.

Financial Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

 
QuoteMedia logo

Head Office

  • 2209 – 1111 Alberni Street
    Vancouver, BC Canada V6E 4V2
  • Phone: (604) 488-8878
  • Fax: (604) 488-0868
  • Toll Free: 1 (866) 833-5517
  • Email: [email protected]

Shanghai Office

  • 06 - 607, 6/f. No.800 Shangcheng
    Road Pudong New District Shanghai,
    China
  • Phone: 021-68883919
  • Fax: 021-68882879
  • Email: [email protected]

Important Links

  • Privacy Policy
  • Terms of Use
  • Content Partner
  • NAI500 Investor Relations Services
  • About Us
  • Contact Us

© 2026 NAI Interactive Ltd. All Rights Reserved

gcff

logo

Website Design Vancouver by Nirvana Canada